US8162121045 - Common Stock
SELECTA BIOSCIENCES INC
NASDAQ:SELB (11/13/2023, 7:15:05 PM)
After market: 0.9 +0.02 (+2.13%)0.8812
-0.08 (-8%)
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts. The company went IPO on 2016-06-22. The firm leverages its ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. The company enables the re-dosing of life-saving gene therapies and restoring self-tolerance in autoimmune diseases. The ImmTOR platform reduces the formation of anti-drug antibodies (ADAs), against biologic drugs and restore self-tolerance to auto-antigens in autoimmune diseases. ImmTOR leverages nanoparticle technology to target rapamycin, an immunomodulatory drug, to antigen presenting cells to generate antigen-specific immune tolerance when combined with the antigen of interest. Its nanoparticles are designed to remain intact after injection into the body and accumulate predominantly in lymph nodes, the spleen, and the liver, where the immune response is coordinated. Its product candidate, SEL-212, which is in Phase III clinical development includes pegadricase, a pegylated uricase enzyme.
SELECTA BIOSCIENCES INC
65 Grove Street
Watertown MASSACHUSETTS 02472
P: 16179231400.0
CEO: Carsten Brunn
Employees: 58
Website: https://selectabio.com/
Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track...
Durable depletion of autoantibodies and clinically meaningful improvements in myasthenia gravis (MG) severity scores observed after one-year follow-up...
– Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian’s wholly...
WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated...
Selecta Biosciences files prospectus for a mixed shelf offering of up to $xx million. Not an offer to sell securities.
Here you can normally see the latest stock twits on SELB, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: